{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":19,"sponsored":0,"items":[{"id":"n_qslpypakhu6qa5k7fjna","seq":1457037,"kind":"article","title":"J&J 먹는 건선약, 2년 지나도 효과 지속…두피·생식기서 높은 개선","title_en":"J&J psoriasis drug, continues to be effective after 2 years... High improvement in scalp and genital areas","url":"https://www.medipana.com/news/articleView.html?idxno=418716","summary":"존슨앤드존슨(J&J)이 개발한 경구용 건선 치료제 \\'이코트로킨라(icotrokinra)\\'가 2년 이상 장기 치료에서도 피부 개선 효과를 유지한 것으로 나타났다. 특히 치료가 까다로운 두피와 생식기, 손·발 등에서 높은 피부 병변 소실률을 보이면서 생물학적 제제가 주도해온 중등도~중증 건선 치료시장에서 경구 치료제의 영역을 넓힐 수 있을지 주목된다. 빅파마 J&J는 2일 중등도 이상의 고영향 부위(high-impact site) 판상건선 환자를 대상으로 이코트로킨라를 평가한 임상 3상 \\'ICONIC-TOTAL\\'의 112주 결과를 공개","published":"2026-10-02T23:43:24Z","seen":"2026-10-03T01:01:11Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_qslpypakhu6qa5k7fjna","category":"health","category_p":0.81,"sentiment":"positive","tone":0.31,"political":0.03},{"id":"n_wywcvtps2ykzmzv2vkfa","seq":1437212,"kind":"article","title":"Johnson & Johnson (NYSE:JNJ) Shares Down 1.1% – What's Next?","url":"https://www.themarketsdaily.com/2026/10/02/johnson-johnson-nysejnj-shares-down-1-1-whats-next.html","published":"2026-10-02T21:52:31Z","seen":"2026-10-02T21:52:31Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","business","disaster","health"],"authors":["Kim Johansen"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_wywcvtps2ykzmzv2vkfa","category":"economy-business","category_p":0.55,"sentiment":"negative","tone":-0.11,"political":0.11},{"id":"n_tap5wlj6iiiravkht3za","seq":1340824,"kind":"article","title":"Analyzing Johnson & Johnson (NYSE:JNJ) and Rafael (NYSE:RFL)","url":"https://www.themarketsdaily.com/2026/10/02/analyzing-johnson-johnson-nysejnj-and-rafael-nyserfl.html","published":"2026-10-02T12:29:03Z","seen":"2026-10-02T12:29:03Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Tristan Rich"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_tap5wlj6iiiravkht3za","category":"economy-business","category_p":0.56,"sentiment":"neutral","tone":0.06,"political":0.1},{"id":"n_ne7ghzn53lqptf7ehu6q","seq":1330246,"kind":"article","title":"Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy","url":"http://www.prnewswire.com/news-releases/johnson--johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy-302896648.html","published":"2026-10-02T11:30:00Z","seen":"2026-10-02T11:33:15Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","politics","health","education"],"authors":["Johnson & Johnson"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_ne7ghzn53lqptf7ehu6q","category":"health","category_p":0.66,"sentiment":"neutral","tone":-0.22,"political":0.04},{"id":"n_abulorlykjbc3pdnr5ea","seq":1281756,"kind":"article","title":"Johnson & Johnson (NYSE:JNJ) Price Target Raised to $285.00","url":"https://www.dailypolitical.com/2026/10/01/johnson-johnson-nysejnj-price-target-raised-to-285-00.html","published":"2026-10-02T06:40:09Z","seen":"2026-10-02T06:40:09Z","lang":"en","source":{"id":"dailypolitical.com","name":"dailypolitical.com","domain":"dailypolitical.com"},"via":"gdelt-gkg-english","topics":["economy","health","business","disaster"],"authors":["Trevor Kearing"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_abulorlykjbc3pdnr5ea","category":"economy-business","category_p":0.85,"sentiment":"positive","tone":0.3,"political":0.05},{"id":"n_h6feni7i762njnl5n6xq","seq":1248886,"kind":"article","title":"BofA thinks Wall Street is underestimating one J&J drug","url":"https://www.aol.com/articles/bofa-thinks-wall-street-underestimating-220300000.html","published":"2026-10-01T22:03:00Z","seen":"2026-10-02T01:54:45Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["AOL"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_h6feni7i762njnl5n6xq","category":"economy-business","category_p":0.5,"category2":"health","sentiment":"neutral","tone":-0.01,"political":0.04},{"id":"n_7eks56t4e3t4kxkszzaq","seq":1238284,"kind":"article","title":"Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?","url":"https://www.fool.com/coverage/better-buy/2026/10/01/johnson-and-johnson-vs-eli-lilly-which-pharma-stock-can-make-your-portfolio-healthier-in-2026?source=iedfolrf0000001","published":"2026-10-01T21:53:00Z","seen":"2026-10-01T23:50:16Z","lang":"en","source":{"id":"fool.com","name":"fool.com","domain":"fool.com","outlet":{"wikidata":"Q7752442","name":"The Motley Fool","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy","politics","health","business"],"authors":["Brendan Coffey"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"},{"id":"Q2984214","name":"Eli Lilly","type":"org"}],"story":"st_7kvgx6diy64cmwrdptwa","category":"economy-business","category_p":0.54,"category2":"health","sentiment":"neutral","tone":0.15,"political":0.01},{"id":"n_owxzglig5oupkjjlxhpa","seq":1208834,"kind":"article","title":"Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale","url":"https://www.aol.com/articles/bristol-myers-squibb-vs-johnson-191502000.html","published":"2026-10-01T19:15:00Z","seen":"2026-10-01T20:13:40Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["AOL"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_n5dm5zufwf7hnuspl2ya","category":"economy-business","category_p":0.54,"sentiment":"neutral","tone":0.09,"political":0.03},{"id":"n_fnb66kkiuf75liqeseva","seq":1030499,"kind":"article","title":"What is Johnson & Johnson's (JNJ) Economic Moat, and is it Widening or Narrowing?","url":"https://www.insidermonkey.com/news/what-is-johnson-johnsons-jnj-economic-moat-and-is-it-widening-or-narrowing-1846741","published":"2026-10-01T01:24:22Z","seen":"2026-10-01T01:24:22Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["business","economy","health"],"authors":["Suraj Santlani"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_fnb66kkiuf75liqeseva","category":"economy-business","category_p":0.95,"sentiment":"neutral","tone":-0.07,"political":0.19},{"id":"n_wy5deaqieqefltf2inuq","seq":994288,"kind":"article","title":"3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High","url":"https://www.aol.com/articles/3-reasons-johnson-johnson-still-192000000.html","published":"2026-09-30T19:20:00Z","seen":"2026-09-30T20:26:51Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["economy"],"authors":["AOL"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_wvzxgqowkzqlycbrosra","category":"economy-business","category_p":0.91,"sentiment":"positive","tone":0.39,"political":0.01},{"id":"n_4lud7b4vkbavvxd726rq","seq":900383,"kind":"article","title":"BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength","url":"https://247wallst.com/investing/2026/09/30/bofa-boosts-abbvie-and-jj-price-targets-on-growth-and-pipeline-strength","published":"2026-09-30T11:15:00Z","seen":"2026-09-30T12:27:07Z","lang":"en","source":{"id":"247wallst.com","name":"247wallst.com","domain":"247wallst.com","outlet":{"wikidata":"Q68896999","name":"24/7 Wall St.","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["disaster","economy","business","health"],"authors":["Vandita Jadeja"],"entities":[{"id":"Q487907","name":"Bank of America","type":"org"},{"id":"Q14662364","name":"AbbVie","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_ppzo2lsrgkclvilb2djq","category":"economy-business","category_p":0.98,"sentiment":"positive","tone":0.42,"political":0.05},{"id":"n_2f2k55tqgod7ydyzmlza","seq":862478,"kind":"press_release","title":"CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J","url":"https://www.globenewswire.com/news-release/2026/09/30/3371624/28124/en/car-t-cell-therapy-market-forecasts-growth-from-7-24b-2026-to-13-78b-by-2031-profiling-bristol-myers-squibb-gilead-sciences-novartis-j-j.html","summary":"The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.…","published":"2026-09-30T08:47:00Z","seen":"2026-09-30T08:56:58Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_2f2k55tqgod7ydyzmlza","category":"health","category_p":0.48,"category2":"economy-business","sentiment":"neutral","tone":0.15,"political":0.02},{"id":"n_oqqev3f54ywnqdb7qzba","seq":728988,"kind":"article","title":"Johnson & Johnson presenta nuevos datos de Tecvayli y Carvykti en la Reunión Anual de la Sociedad Internacional de Mieloma (IMS)","title_en":"Johnson & Johnson presents new data on Tecvayli and Carvykti at the Annual Meeting of the International Myeloma Society (IMS)","url":"https://gacetamedica.com/investigacion/johnson-johnson-nuevos-datos-tecvayli-carvykti-reunion-anual-sociedad-internacional-mieloma","summary":"Un nuevo análisis basado en modelos refuerza el potencial de Tecvayli en combinación con daratumumab para redefinir las expectativas de supervivencia a largo plazo en pacientes con mieloma múltiple en recaída o refractario en líneas tempranas de tratamiento; mientras que Carvykti logra remisiones libres de tratamiento durante cinco años en el 50% de los pacientes con mieloma múltiple en recaída o refractario en líneas tempranas The post Johnson & Johnson presenta nuevos…","published":"2026-09-29T16:29:00Z","seen":"2026-09-29T17:22:03Z","lang":"es","source":{"id":"kite-gacetamedica-com-5d5bef","name":"gacetamedica.com","domain":"gacetamedica.com"},"via":"kite-gacetamedica-com-5d5bef","topics":["medicine","investigación","carvykti","johnson & johnson","mieloma múltiple","tecvayli"],"authors":["Gaceta Médica"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"},{"id":"Q140871629","name":"International Myeloma Society","type":"org"}],"story":"st_oqqev3f54ywnqdb7qzba","category":"health","category_p":0.62,"sentiment":"neutral","tone":0.11,"political":0.09},{"id":"n_ga4jpopeqevw6hfk4x2q","seq":681153,"kind":"article","title":"J&J Reports Two-Year IMAAVY Data Showing Sustained Disease Control In GMG","url":"https://www.rttnews.com/3694833/j-j-reports-two-year-imaavy-data-showing-sustained-disease-control-in-gmg.aspx","published":"2026-09-29T13:16:00Z","seen":"2026-09-29T13:40:32Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_5swuswcrkpmkzkihm36q","category":"health","category_p":0.79,"sentiment":"positive","tone":0.07,"political":0.03},{"id":"n_5swuswcrkpmkzkihm36q","seq":676586,"kind":"article","title":"J&J's IMAAVY Shows Sustained Disease Control In New GMG Data","url":"https://www.finanzen.ch/nachrichten/aktien/j&js-imaavy-shows-sustained-disease-control-in-new-gmg-data-1036581399","published":"2026-09-29T13:09:24Z","seen":"2026-09-29T13:09:24Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","politics","health"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"},{"id":"Q2665980","name":"Guardian Media Group","type":"other"}],"story":"st_5swuswcrkpmkzkihm36q","category":"health","category_p":0.71,"sentiment":"positive","tone":0.21,"political":0.02},{"id":"n_k42thgcw6cvdeyihc7tq","seq":550113,"kind":"article","title":"Is Johnson & Johnson (JNJ) Building a Stronger Post-Stelara Growth Story?","url":"https://www.insidermonkey.com/news/is-johnson-johnson-jnj-building-a-stronger-post-stelara-growth-story-1845412","published":"2026-09-29T00:43:39Z","seen":"2026-09-29T00:43:39Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["disaster","economy","health","business"],"authors":["Laiba Immad"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_k42thgcw6cvdeyihc7tq","category":"economy-business","category_p":0.9,"sentiment":"neutral","tone":0.23,"political":0.02},{"id":"n_ajcyqe4uvpv2saplekhq","seq":514874,"kind":"article","title":"Can J&J's Partnership Drive More Upside for Nanobiotix?","url":"https://www.insidermonkey.com/news/can-jjs-partnership-drive-more-upside-for-nanobiotix-1845930","published":"2026-09-28T20:08:19Z","seen":"2026-09-28T20:08:19Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Noor Ul Ain Rehman"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"},{"id":"Q6963996","name":"Nanobiotix","type":"org"}],"story":"st_ajcyqe4uvpv2saplekhq","category":"economy-business","category_p":0.64,"sentiment":"positive","tone":0.37,"political":0.03},{"id":"n_drjzvyitmgy33inrtmqa","seq":513547,"kind":"article","title":"Can J&J's Latest Trial Win Strengthen its Neuroscience Business?","url":"https://www.insidermonkey.com/news/can-jjs-latest-trial-win-strengthen-its-neuroscience-business-1845917","published":"2026-09-28T20:08:19Z","seen":"2026-09-28T20:08:19Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Noor Ul Ain Rehman"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_drjzvyitmgy33inrtmqa","category":"economy-business","category_p":0.65,"sentiment":"positive","tone":0.12,"political":0.01},{"id":"n_fczixcdlvjdmnsiv7rjq","seq":509130,"kind":"article","title":"Johnson & Johnson's Next Growth Engine Is Taking Shape","url":"https://247wallst.com/investing/2026/09/28/johnson-johnsons-next-growth-engine-is-taking-shape","published":"2026-09-28T18:00:00Z","seen":"2026-09-28T19:37:15Z","lang":"en","source":{"id":"247wallst.com","name":"247wallst.com","domain":"247wallst.com","outlet":{"wikidata":"Q68896999","name":"24/7 Wall St.","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","disaster","health"],"authors":["Vandita Jadeja"],"entities":[{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_nzid3jmzicgeonw7lamq","category":"economy-business","category_p":0.69,"category2":"science-technology","sentiment":"positive","tone":0.2,"political":0.02}]}